Every mass tort has a moment when the abstract becomes concrete. For the more than 10,000 people who have sued Medtronic over its Covidien hernia mesh products, that moment arrived on August 4, 2026, in a federal courtroom in Boston. After a three-week trial, a jury awarded $88 million to Larry and Tammy Patterson: $77 million to Mr. Patterson for his injuries and $11 million to his wife for loss of consortium.

The number is remarkable on its own. Reuters reported it was by far the largest in more than a dozen hernia and transvaginal mesh trials, and plaintiffs' counsel described it as the highest compensatory award in the history of mesh litigation. But the more consequential fact for the litigation is how the jury got there. This was a failure-to-warn case, and it was won on the testimony of the defendant's own executives.

The Product and the Promise

Composite hernia meshes are engineered to solve a problem that has plagued abdominal surgery for decades: permanent synthetic mesh provides durable structural support, but bare mesh placed against the bowel can cause the intestine to adhere to it, leading to obstruction, fistula, and revision surgery. The solution is a resorbable barrier on the visceral side of the mesh that separates it from the organs during the critical healing window.

Covidien's Symbotex Composite Mesh used a collagen barrier for that purpose. According to the evidence at trial, surgeons were led to expect the barrier to remain effective for roughly 30 days. The Pattersons alleged that the porcine collagen used in Symbotex actually resorbed in about seven days, and that Covidien continued to supply surgeons with information derived from an earlier bovine collagen formulation that lasted longer. Trade press coverage of the verdict summarized the plaintiffs' theory the same way: the company knew porcine collagen degraded faster and did not tell the physicians relying on it.

Mr. Patterson, an Alabama resident implanted with Symbotex during a 2017 hernia repair, developed a bowel obstruction that required a second operation in 2020. Surgeons removed the mesh along with several inches of his intestine. He was 61 at trial.

What the Jury Actually Found

Precision matters here, because the verdict has already been described in ways that overstate and understate it. According to reporting on the verdict form, the jury found:

• Covidien failed to provide an adequate warning about the risks of Symbotex, and that failure caused harm.
• Covidien concealed an important fact about the mesh, and that concealment caused harm.
• Covidien did not intentionally or recklessly make false statements; the jury rejected the fraud claim.
• No punitive damages were awarded. The entire $88 million is compensatory.

That last point deserves emphasis. Juries that are angry award punitive damages. This jury was not asked to punish; it was asked to compensate, and it valued the harm to one man and his wife at $88 million. Plaintiffs' co-lead counsel Timothy O'Brien of Levin Papantonio told reporters the award reflected "very substantial damages," and Medtronic has said it will challenge the verdict through post-trial motions and appeal. Both statements are consistent with the record: a compensatory award of this size will face rigorous review, and the absence of punitive damages narrows the grounds on which it can be attacked.

The Defense the Jury Rejected

Covidien denied the allegations throughout. Its defense had two prongs. First, that physicians were adequately warned and that mesh has long been the standard of care for hernia repair, a point the company reiterated in its post-verdict statement. Second, that Mr. Patterson's medical history, including obesity and diabetes, and the conduct of his surgeon, rather than any product defect, explained his injuries.

The second argument is a familiar one in device litigation, and it is not frivolous. Comorbidities do affect surgical outcomes. But it carries a structural risk for the defense: if the jury concludes the company withheld information the surgeon needed, blaming the surgeon for acting without that information tends to backfire. According to the plaintiffs' account of the trial, the jury heard high-ranking Covidien and Medtronic witnesses concede on cross-examination that the barrier did not function past seven days. Once that concession is in the record, the surgeon's decision looks less like error and more like reliance.

The case reached the jury largely intact. In June 2026, Judge Patti B. Saris denied most of Covidien's summary judgment motion, finding Patterson had presented enough evidence, including internal studies and company scientists' testimony, that the company may have knowingly failed to warn physicians how quickly the collagen barrier degraded.

Where the Litigation Stands

The Patterson case, No. 1:22-cv-10153, is a member case in In re: Covidien Hernia Mesh Products Liability Litigation No. II, MDL No. 3029, pending before Judge Saris in the District of Massachusetts. Roughly 2,400 to 2,500 cases are consolidated there. A far larger group, about 7,450 plaintiffs, has filed in Massachusetts state court, where Covidien is headquartered. Reuters put the national total at approximately 10,350 plaintiffs across the Parietex, ProGrip, and Symbotex product lines.

The MDL's Master Long Form Complaint alleges the devices were defectively designed and inadequately tested, marketed, and labeled, and that patients may suffer adhesions, chronic inflammation, infection, bowel obstruction, recurrent hernia, chronic pain, and the need for revision surgery. Covidien disputes each allegation. Judge Saris appointed O'Brien and Kelsey Stokes (now of Stokes & Hobbs) as plaintiffs' co-lead counsel in September 2023; both tried the Patterson case.

As of early October 2026, the verdict is not final. Medtronic has said it will challenge the award through post-trial motions and, if necessary, an appeal, and no ruling on that challenge has been publicly reported.

The Next Two Trials

In an order issued August 25, 2026, Judge Saris set the second bellwether trial to begin on January 11, 2027. It involves claims by Regina Stephen of Mississippi, who was implanted with Symbotex during a 2017 ventral hernia repair and underwent surgery in July 2020 to remove the mesh after developing small bowel adhesions. The order calls for a pretrial memorandum by December 1, 2026, and a final pretrial conference on December 10.

A third trial, involving a Covidien ProGrip mesh, is tentatively scheduled for March 2027. That sequencing matters. The second trial will test whether the Symbotex theory that persuaded the Patterson jury holds up with a different plaintiff; the third will test whether liability extends beyond Symbotex to another product line.

What a Bellwether Does, and Does Not, Decide

A bellwether verdict binds only the parties to that case. It does not establish liability for any other plaintiff, each of whom must still prove that a specific product caused a specific injury under the law of the applicable state. Anyone who tells a hernia mesh claimant that the Patterson verdict guarantees a recovery is misleading them.

What a bellwether does is supply information neither side previously had. Before August 4, Medtronic could model its exposure on the assumption that juries would find comorbidities persuasive and warnings adequate. After August 4, that assumption carries a demonstrated cost. Before August 4, plaintiffs' counsel could only estimate how a jury would value a bowel resection and a lifetime risk of further surgery. Now there is a data point, and it is a large one.

This is why bellwethers so often precede settlement discussions. The Bard hernia mesh MDL in Ohio, the Ethicon Physiomesh MDL in Georgia, and the Atrium C-QUR MDL in New Hampshire each moved toward resolution after trial results clarified the range. Bard, for example, reached a settlement in October 2025 designed to resolve a large share of its more than 25,000 hernia mesh claims. The Covidien litigation has now produced its first result, with two more trials set for early 2027.

What Claimants and Counsel Should Watch

1. Post-trial motions and appeal. Medtronic has said it will seek to overturn or reduce the award. The compensatory-only structure of the verdict makes a wholesale reversal less likely than a reduction, but the First Circuit may have the final word.
2. The January 11, 2027 trial. A second Symbotex plaintiff verdict would materially change settlement leverage; a defense verdict would restore some of Medtronic's bargaining position.
3. The ProGrip trial in March 2027. A plaintiff result there would show the litigation reaches beyond a single product; a defense result would narrow it.
4. Label changes. Co-lead counsel Stokes has publicly argued that the litigation will keep growing as long as the Symbotex label does not reflect the seven-day resorption evidence. Any label revision would be significant.
5. State-court coordination. With roughly three times as many cases in Massachusetts state court as in the MDL, any global resolution will have to bridge both forums.

For the thousands of patients behind the Pattersons, the verdict does not end anything. It begins the part of a mass tort where the numbers finally have meaning.

Key Takeaways

• On August 4, 2026, a Boston federal jury awarded $88 million ($77M to Larry Patterson, $11M to Tammy Patterson) in the first Covidien hernia mesh bellwether, Patterson v. Covidien, MDL 3029.
• The jury found failure to warn and concealment, rejected fraud, and awarded no punitive damages; the entire award is compensatory.
• The central evidence was that Symbotex's porcine collagen barrier resorbed in about seven days while surgeons were led to expect about 30.
• Roughly 2,400 to 2,500 cases are pending in the MDL and about 7,450 more in Massachusetts state court, for approximately 10,350 plaintiffs nationwide.
• Medtronic is challenging the verdict. The second bellwether (Symbotex) is set for January 11, 2027, and a third (ProGrip) is tentatively set for March 2027. No other plaintiff's claim is decided by this verdict.

Frequently Asked Questions

What is the Covidien hernia mesh lawsuit about?

Plaintiffs allege that Covidien (a Medtronic subsidiary) designed, tested, and labeled its Parietex, ProGrip, and Symbotex hernia meshes defectively, and that patients suffered adhesions, bowel obstruction, infection, chronic pain, and revision surgeries as a result. Covidien denies the allegations.

How much was the first Covidien hernia mesh verdict?

$88 million, awarded August 4, 2026, by a federal jury in Boston: $77 million to Larry Patterson and $11 million to his wife Tammy for loss of consortium. It is reported to be the largest compensatory award in U.S. mesh litigation.

Did the jury find Medtronic committed fraud?

No. The jury found failure to warn and concealment but rejected the claim that Covidien intentionally or recklessly made false statements, and it awarded no punitive damages.

When is the next Covidien hernia mesh trial?

The second bellwether trial, involving Regina Stephen of Mississippi and a Symbotex mesh, is scheduled to begin January 11, 2027. A third trial involving a ProGrip mesh is tentatively scheduled for March 2027.

Where is the Covidien hernia mesh MDL?

MDL No. 3029, In re: Covidien Hernia Mesh Products Liability Litigation No. II, is pending before Judge Patti B. Saris in the U.S. District Court for the District of Massachusetts. A larger group of cases is coordinated in Massachusetts state court.

Does the verdict mean other hernia mesh plaintiffs will win?

No. A bellwether verdict binds only the parties in that case. It provides information about how a jury evaluated the evidence, which influences settlement negotiations, but every plaintiff must still prove causation and injury.

About the Author

Fadi Agour, J.D., is a licensed attorney and the founder and CEO of FadiLaw Marketing LLC, the Houston-based parent company of Best Case Leads, Real Performance Marketing, Masstortsco, and Redostar. For more than seven years he has built performance-marketing companies that connect injured consumers with the plaintiff law firms equipped to represent them. His companies have earned a place on the Inc. 5000 list of America's fastest-growing private companies seven consecutive times (7x Badge). He writes about mass tort litigation, product liability, and the business of plaintiff law.

Sources and Further Reading

6. Reuters via U.S. News & World Report, "US Jury Says Medtronic Owes $88 Million in First Case to Go to Trial Over Covidien's Hernia Mesh" (Aug. 4, 2026): https://www.usnews.com/news/us/articles/2026-08-04/us-jury-says-medtronic-owes-88-million-in-first-case-to-go-to-trial-over-covidiens-hernia-mesh
7. Star Tribune, "Jury rules Medtronic owes $88M in first case about hernia treatment products" (Aug. 2026): https://www.startribune.com/jury-federal-bellwether-medtronic-covidien-mesh-hernia-88-million/601874963
8. MassDevice, "Jury says Medtronic must pay $88M in Covidien hernia mesh suit" (Aug. 5, 2026): https://www.massdevice.com/jury-medtronic-88m-hernia-mesh-suit/
9. Medical Daily, "Jury Orders Medtronic to Pay $88 Million After Finding Surgeons Were Not Adequately Warned About a Hernia Mesh" (Aug. 2026): https://www.medicaldaily.com/medtronic-covidien-hernia-mesh-88-million-verdict-failure-warn-477059
10. Newsfile Corp., "$88 Million Verdict in First Federal Covidien Hernia Mesh Bellwether Trial" (Aug. 15, 2026), including case caption Patterson v. Covidien Inc., No. 1:22-cv-10153: https://www.newsfilecorp.com/release/309712/88-Million-Verdict-in-First-Federal-Covidien-Hernia-Mesh-Bellwether-Trial
11. Top Class Actions, "Covidien hit with $88M verdict in first bellwether hernia mesh trial" (citing Law360; June 2026 summary judgment ruling): https://topclassactions.com/lawsuit-settlements/lawsuit-news/covidien-hit-with-88m-verdict-in-first-bellwether-hernia-mesh-trial/
12. com, "Judge Sets Next Covidien Hernia Mesh Lawsuit for Trial in January 2027" (Sept. 11, 2026), citing the Aug. 25, 2026 order: https://www.aboutlawsuits.com/hernia-mesh-1364/judge-covidien-hernia-mesh-lawsuit-trial-january-2027/
13. Levin Papantonio, newsroom statement on the Patterson verdict: https://levinlaw.com/newsroom/first-covidien-bellwether-settlement/
14. S. District Court for the District of Massachusetts, In re: Covidien Hernia Mesh Products Liability Litigation No. II, MDL No. 3029 (Saris, J.).

 

This article is provided for general informational and educational purposes only. It is not legal advice, does not create an attorney-client relationship, and should not be relied upon as a substitute for consultation with a licensed attorney about your specific circumstances. Allegations in pending litigation described here have not been adjudicated, and defendants deny them. Case status, settlement terms, and deadlines change; verify current information with counsel.